Multipronged system proactively detects and prevents biorisk
Our extensive process includes screening platform users, customers, user-uploaded genomes (e.g., from organisms that are not an Inscripta strain), as well as every design library ordered. We trust approved customers, so in silico sequence screening primarily targets accidental creation of a biorisk or a dual use scenario.
We follow industry standard practices.
We screen customer information against government banned lists.
We computationally screen customer genomes.
This screening includes a first pass at biorisk detection, comparing customer genomes against known genes that may cause harm.
The next phase of screening is an in silico screen of all customer-directed edits, using a functional biorisk prediction algorithm.
Matches will invoke manual verification and, if warranted, our Customer Success Team will engage in discussion with the customer.
Impossible just got push-button easy. Meet the future with Inscripta™ and Digital Genome Engineering.